- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Anxiety/Depression Symptoms Improve in Patients With Cancer After Using Stress Management App
June 3rd 2023, 11:29pm
Positive changes in symptoms of anxiety and depression were reported in patients with cancer following the use of a cognitive behavioral stress management app.
Linvoseltamab Shows High Response Rate, Manageable Toxicity for Pretreated Myeloma
June 3rd 2023, 11:18pm
The BCMA/CD3 bispecific linvoseltamab elicited an objective response rate of 71% at the recommended dose of 200 mg for patients with relapsed/refractory multiple myeloma.
PHE855 Generates High Response and MRD Negativity Rates in Relapsed/Refractory Myeloma
June 3rd 2023, 10:55pm
The CAR T-cell therapy PHE885 produced responses and high minimal residual disease negativity rates with no new safety signals in patients with relapsed/refractory multiple myeloma.
Teclistamab/Talquetamab Combo Shows Early Safety, Efficacy in R/R Multiple Myeloma
June 3rd 2023, 10:18pm
Teclistamab-cqyv in combination with talquetamab showcased early signs of activity with acceptable safety in patients with relapsed/refractory multiple myeloma, according to final results from the phase 1b RedirecTT-1 study.
Efficacy of CLDN6-Directed CAR T Therapy Is Maintained With Automated Manufacturing in Solid Tumors
June 3rd 2023, 10:10pm
When manufactured via automated process the CLDN6-directed CAR T-cell therapy, BNT211, demonstrated encouraging signs of activity and a manageable safety profile with or without the addition of CLDN6-encoding mRNA vaccine in patients with CLDN6-positive relapsed/refractory advanced solid tumors.
Subsequent Treatments Feasible After Radium-223 in mCRPC
June 3rd 2023, 9:52pm
Radium-223 was safe and did not preclude patients with metastatic castration-resistant prostate cancer from receiving subsequent life-prolonging therapies, including chemotherapy.
Belzutifan/Lenvatinib Elicits Responses in Advanced ccRCC After Progression on ICI and VEGF TKI
June 3rd 2023, 8:35pm
Belzutifan plus lenvatinib generated responses and displayed a manageable safety profile in patients with advanced clear cell renal cell carcinoma whose disease progressed following treatment with a PD-1/L1 inhibitor and a VEGF TKI.
Talazoparib Plus Enzalutamide Has Manageble Toxicity With Dose Modifications, Supportive Care in mCRPC
June 3rd 2023, 6:44pm
The use of talazoparib plus enzalutamide was manageable with dose modifications or standard supportive care treatment in patients with metastatic castration-resistant prostate cancer.
Real-World Data Detail Potential Benefits of Darolutamide Over Other ARIs in nmCRPC
June 3rd 2023, 5:03pm
Patients with nonmetastatic castration-resistant prostate cancer who received darolutamide were observed to have a longer time to treatment discontinuation and progression to metastatic castration-resistant disease than those who received enzalutamide or apalutamide.
Perioperative Pembrolizumab Shows Strong EFS, Response in Early-Stage NSCLC
June 3rd 2023, 4:08pm
The addition of pembrolizumab to neoadjuvant platinum-based chemotherapy followed by resection and adjuvant pembrolizumab alone resulted in a significant improvement in event-free survival and pathological response for patients with early-stage non–small cell lung cancer.
Zanidatamab Elicits Responses in HER2-amplified Advanced Biliary Tract Cancer
June 3rd 2023, 3:58pm
Zanidatamab generated responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer who were previously treated with gemcitabine.
NALIRIFOX Elicits Statistically Significant Improvement in OS/PFS in Previously Untreated mPDAC
June 3rd 2023, 3:18pm
Liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin generated statistically significant and clinically meaningful overall survival and progression-free survival benefits compared with gemcitabine plus nab-paclitaxel in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma.
HIMALAYA Safety Data Support STRIDE Regimen as A Global Treatment Option for uHCC
June 3rd 2023, 2:16pm
Patients with unresectable hepatocellular carcinoma experienced manageable and low-grade immune-related adverse events with single tremelimumab regular interval durvalumab.
Addition of Up-front Durvalumab, Maintenance Olaparib to Standard Therapy Improves PFS in Advanced Ovarian Cancer
June 3rd 2023, 12:00pm
The addition of durvalumab to standard upfront therapy with chemotherapy and bevacizumab followed by maintenance bevacizumab, durvalumab, and olaparib led to a statistically significant improvement in progression-free survival compared with chemotherapy and bevacizumab alone in patients with newly diagnosed, advanced ovarian cancer without a BRCA1/2 mutation.
Efficacy and Safety of Abemaciclib Plus ET Is Maintained Older Patients with HR+, HER2–, Early Breast Cancer
June 3rd 2023, 12:01am
A clinically meaningful absolute risk reduction in invasive disease-free survival and distant relapse-free survival with abemaciclib plus endocrine therapy was maintained in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer regardless of age.
Retrospective Study Confirms Real-World Efficacy of Brexucabtagene Autoleucel in R/R B-ALL
June 2nd 2023, 11:22pm
Brexucabtagene autoleucel elicited high rates of complete remission with minimal residual disease negativity in real-world patients with relapsed or refractory B-cell acute lymphoblastic leukemia who received the CAR T-cell product as post-approval, standard-of-care treatment, according to data from a retrospective study.
Dr Garcia-Manero on Luspatercept in Lower-Risk MDS
June 2nd 2023, 11:20pm
Guillermo Garcia-Manero, MD, discusses key efficacy and safety findings from the phase 3 COMMANDS trial (NCT03682536) of luspatercept-aamt (Reblozyl) vs epoetin alfa in patients with lower-risk myelodysplastic syndrome.
Dr Zeidan on Imetelstat in Lower-Risk MDS
June 2nd 2023, 11:15pm
Amer Zeidan, MBBS, discusses topline efficacy findings from the IMerge trial of imetelstat in patients with transfusion-dependent lower-risk myelodysplastic syndrome.
Obe-cel Elicits 76% CR/CRi Rate, 97% MRD-Negativity Rate in Relapsed/Refractory B-ALL
June 2nd 2023, 11:10pm
Obecabtagene autoleucel was associated with a 76% complete response (CR)/CR with incomplete count recovery rate in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Imetelstat Prolongs Transfusion Independence, Increases Hemoglobin in R/R MDS
June 2nd 2023, 11:02pm
Treatment with the first-in-class direct and competitive telomerase inhibitor imetelstat resulted in statistically significant and clinically meaningful efficacy in patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome that is relapsed or refractory to erythropoiesis stimulating agents, according to findings from the phase 3 IMerge trial.